Optimistic assumptions in modelling studies have a substantial influence on the cost-effectiveness result [9]

Rheumatology

Volumn 42, Issue 12, 2003, Pages 1574-1575

  Welsing, P M J ^b   Severens, J L ^a   Laan, R F J M ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INFLIXIMAB; METHOTREXATE;

CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; HUMAN; LETTER; MEDICAL SPECIALIST; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; HUMANS; MODELS, ECONOMETRIC; RESEARCH DESIGN;

EID: 0344237248     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg456     Document Type: Letter

References (6)

1. Kobelt G, Jönssen L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42:326-35.
2. Gabriel SE, Tugwell P, Drummond M. Meeting report. Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology.
3. Weinstein MC, O'Brien BJ, Hornberger J et al. Principles of good practice of decision analytic modeling in health care evaluation: Report of the ISPOR Task Force in Good Research Practices - Modeling Studies. Value Health 2003;6: 9-17.
4. Richardson WS, Detsky AS. Users' guide to the medical literature. VII How to use a clinical decision analysis. A. Are the results of the study valid? J Am Med Assoc 1995;273:1292-5.
5. Buxton JM, Drummond ME, van Hout BA et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217-27.
6. Kassirer JP, Angell M. The journal's policy on cost-effectiveness analyses. N Engl J Med 1994:331:669-70.